- Home
- SGHT vs SLN Comparison
SGHT vs SLN Comparison
Compare SGHT & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- SLN
- Stock Information
- Founded
- SGHT 2011
- SLN 1994
- Country
- SGHT United States
- SLN United Kingdom
- Employees
- SGHT N/A
- SLN N/A
- Industry
- SGHT Medical Specialities
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- SLN Health Care
- Exchange
- SGHT Nasdaq
- SLN Nasdaq
- Market Cap
- SGHT 140.1M
- SLN 165.3M
- IPO Year
- SGHT 2021
- SLN N/A
- Fundamental
- Price
- SGHT $3.03
- SLN $3.70
- Analyst Decision
- SGHT Buy
- SLN Buy
- Analyst Count
- SGHT 7
- SLN 5
- Target Price
- SGHT $3.92
- SLN $32.60
- AVG Volume (30 Days)
- SGHT 161.2K
- SLN 254.2K
- Earning Date
- SGHT 05-08-2025
- SLN 05-08-2025
- Dividend Yield
- SGHT N/A
- SLN N/A
- EPS Growth
- SGHT N/A
- SLN N/A
- EPS
- SGHT N/A
- SLN N/A
- Revenue
- SGHT $78,109,000.00
- SLN $27,701,000.00
- Revenue This Year
- SGHT N/A
- SLN N/A
- Revenue Next Year
- SGHT $11.17
- SLN N/A
- P/E Ratio
- SGHT N/A
- SLN N/A
- Revenue Growth
- SGHT N/A
- SLN N/A
- 52 Week Low
- SGHT $2.03
- SLN $1.97
- 52 Week High
- SGHT $8.45
- SLN $24.38
- Technical
- Relative Strength Index (RSI)
- SGHT 56.13
- SLN 55.23
- Support Level
- SGHT $2.81
- SLN $3.54
- Resistance Level
- SGHT $3.26
- SLN $4.15
- Average True Range (ATR)
- SGHT 0.24
- SLN 0.33
- MACD
- SGHT -0.01
- SLN 0.06
- Stochastic Oscillator
- SGHT 38.57
- SLN 53.62
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.